INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Article

Pharmacogenomics and Big Data in Medical Oncology: - Development, Integration Challenges and Future Perspectives.

Dhanashree Somawanshi*[1], Dhanashri Gosavi[1], Devesh Bhavsar[2]

[1]KES's Late Shri P.C.B.College of D.Pharmacy & Late Prof.R.K.kele College of B.Pharmacy, Amalner, Dist Jalgaon, India
[2]Assistant Professor, KES's Late Shri P.C.B.College of D.Pharmacy & Late Prof.R.K.kele College of B.Pharmacy, Amalner, Dist Jalgaon, India

ARTICLE INFO

Published: 27 May. 2026
Keywords:
Medical oncology, personalized medicine, CRISPR, Immunogenics, precision oncology.
DOI:
10.5281/zenodo.20403803

ABSTRACT

Medical oncology continues to play a significant role in the treatment of cancer patients, especially those with systemic disease, using both targeted medications and traditional chemotherapy. Drug resistance and severe normal tissue toxicity are two issues that still exist despite advancements in every aspect of medical oncology. Healthcare professionals can customize medication therapy for each patient based on their genetic composition by incorporating pharmacogenomic data into clinical decision-making processes. This maximizes treatment results while reducing side effects. Pharmacogenomic testing is essential in oncology for identifying targeted medicines based on patients' genetic profiles, predicting chemotherapy response, and customizing cancer treatment.Ongoing research in polygenic risk scores, liquid biopsies, gene–drug interaction networks, and immunogenomics promises to further refine pharmacogenomic applications, improving patient outcomes and reducing treatment-related adverse events.This review also discusses the challenges and future directions in pharmacogenomics, including the integration of computational models and CRISPR-based gene editing to better understand gene–drug interactions and resistance mechanisms. The clinical implemen-tation of pharmacogenomics has the potential to optimize cancer treatment by tailoring therapies to an individual's genetic profile, ultimately enhancing therapeutic efficacy and minimizing toxicity.

INTRODUCTION

All medication-related treatments used to treat cancer are included in medical oncology. Medical

***Corresponding Author:** Dhanashree Somawanshi
Address: *KES's Late Shri P.C.B.College of D.Pharmacy & Late Prof.R.K.kele College of B.Pharmacy, Amalner, Dist Jalgaon, India*
Email ✉: dhanashreesomawanshi66@gmail.com
Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

oncology is an essential aspect of the therapeutic process for all malignancies, especially for systemic, disseminated cancer when surgery and/or radiation therapy are not practical possibilities.(13) the oldest area of medical oncology is conventional chemotherapy, which is followed by immunotherapy and targeted therapies, the latter of which are more focused on specific targets. However, as a component of the majority of solid and haematological cancer treatments, conventional chemotherapy continues to remain the mainstay of medical oncology. Drug-based therapies have a number of drawbacks that frequently restrict their use, making treatment less effective. Clinical research over the years has shown that although one proportion of patients gets long-term control without significant toxicities, another subgroup consistently experiences severe side effects and/or suboptimal treatment response. Investigations into these issues revealed that certain genes and gene variations cause substantial normal tissue damage in a variety of cancer forms as well as specific medication resistance.In order to (13) create a more individualized approach to treatment based on the genetic makeup of the patient and eliminate the one-size-fits-all approach, (9) stratify patients based on genetic evidence in clinical trials, and (8) reduce trial-and-error associated with drug administration, a new research field was created to examine the associations between genes and response to drug therapy . By utilizing extensive drug and gene databases and applying algorithms for identifying correlations between drug–gene pair interactions, pharmacogenomics—often confused with pharmacogenetics, which primarily refers to genetic causes of individual rather than multiple genetic variations in drug response—is a very promising field that can address the aforementioned chemotherapy-related challenges. The purpose of this narrative review is to outline the function and developments in pharmacogenomics.(37)

Insights into Pharmacogenomics

Pharmacogenomics studies the effects of genetic differences on pharmacological responsiveness, effectiveness and side effects. Variability in medication efficacy and toxicity can result from genetic variants in drug-metabolizing enzymes, drug transporters, and drug targets that change pharmacokinetics and pharmacodynamics.

1. Genetic variations in the cytochrome P450 (CYP) family of enzymes, for instance, might impact the metabolism of different medications, affecting both their therapeutic and adverse effects.(8,9)

2. Clinical Practice Applications Customized Drug Therapy By finding genetic markers linked to drug response, pharmacogenomic testing allows clinicians to customize drug therapy. For example, in patients receiving antiplatelet medication, genetic testing for CYP2C19 polymorphisms can direct the choice and dosage of clopidogrel.

3. By customizing treatment plans, medical professionals can maximize therapeutic results and reduce side effects.(37)

Important Advances in Pharmacogenomics for Oncology:-

In order to reduce toxicity, germline pharmacogenomics finds inherited genetic variations that affect drug pharmacokinetics, or how the body breaks down medication, and pharmacodynamics, or how the drug affects the body.(47) By focusing on acquired mutations in tumor DNA, somatic pharmacogenomics assists medical professionals in determining specific

therapeutic targets and forecasting a tumor's response.

Principal Clinical Applications:

DPYD Testing:-To prevent serious, potentially fatal toxicities, testing for DPYD variations is essential for patients using fluoropyrimidines (such as capecitabine and 5-fluorouracil).TPMT/NUDT15 testing is essential for controlling thiopurine dosage in leukemias in order to prevent toxicity.(1)

- **UGT1A1 Testing: -**To treat severe neutropenia, Irinotecan dosage is determined by UGT1A1 variations.
- **HER2 testing:-**It is used to evaluate the potential of cardiac damage in patients on trastuzumab.Pharmacogenomics is being used more and more in drug development and phase I trials to find patient subgroups that have a high risk of toxicity or a high chance of responding.(45)
- **The Future: -**Big Data & Liquid Biopsies: In order to offer real-time updates on tumor mutations, maximize treatment efficacy, and minimize side effects, the future of oncology PGx will make use of enormous datasets and non-invasive liquid biopsies (checking circulating tumor DNA)Figure



Figure 1. The aims of personalized medicine include the understanding of genetic variability, tumor heterogeneity, and medical context (health records, medical imaging, staging).

Historical milestone of pharmacogenomics in medical oncology:-

Table: 1 Timeline of key milestone.(43,54)

Year	Milestone	Significance in Medical Oncology
1950's	Glucose-6-phosphate dehydrogenase deficiency & primaquine hemolysis	First link between genetics and drug toxicity. Concept of "pharmacogenetics" born. Laid groundwork for oncology PGx
1980	Glucose-6-phosphate dehydrogenase deficiency & primaquine hemolysis	Weinshilboum & Sladek identify TPMT deficiency causing fatal myelosuppression in leukemia patients on 6-MP. First oncology PGx test
1998	HER2/neu & Trastuzumab approval by FDA	First "companion diagnostic" in oncology. IHC/FISH for HER2 guides Herceptin use in breast cancer. Start of targeted PGx

2000	Human Genome Project draft completed	Enabled large-scale discovery of germline + somatic variants relevant to drug response
2004	UGT1A1*28 & Irinotecan label update by FDA	FDA mandates PGx testing warning for Gilbert syndrome patients: risk of severe neutropenia. First oncology drug with PGx in label
2005	EGFR mutations & Gefitinib response	Lynch et al. show EGFR exon 19/21 mutations predict response in NSCLC. Shift from histology to genotype-guided therapy
2008	KRAS mutations & Cetuximab resistance	Amado et al. prove KRAS-mutant colorectal cancer does not benefit from anti-EGFR. FDA mandates KRAS testing
2009	PharmGKB & CPIC founded	Curated knowledgebase + clinical guidelines for PGx. Oncology drugs get level 1A evidence

Pharmacogenomics Principles:

The study of how genetic diversity impacts a person's reaction to medications is known as pharmacogenomics, and it includes both pharmacokinetics (PK), or how a drug affects the body, and pharmacodynamics (PD), or how a drug affects the body. (19)The effectiveness and safety of a particular medication can be determined by these genetic variations, which can have a substantial impact on drug absorption, distribution, metabolism, excretion (ADME), and interaction with biological targets.(18)



Figure 2: Pharmacogenomics Principles

Drug Metabolism and Genetic Variability:

Genetic polymorphisms in drug-metabolizing enzymes, especially the cytochrome P450 (CYP450) family, are one of the most well-established areas of pharmacogenomics. (58,59) About 75% of all prescription medications undergo oxidative metabolism due to these enzymes.(30,44)

Important polymorphic enzymes consist following:

- CYP2D6: In charge of the metabolism of several beta-blockers, opioids, and antidepressants. Phenotypes of poor, intermediate, extensive, or ultra-rapid metabolizers are caused by genetic variations. (26)

- CYP2C9 and CYP2C19: Variants impact proton pump inhibitors, warfarin, and phenytoin metabolism.

- CYP3A4 and CYP3A5: They affect the metabolism of many medications, such as statins and immunosuppressants. While ultra-rapid metabolizers may have subtherapeutic levels, leading to treatment failure, people with decreased enzyme activity may face drug buildup and toxicity.

- Drug Transport and Distribution: Drug bioavailability and tissue distribution are also significantly influenced by genetic variations in drug transporter proteins. (18)

- ABCB1 (MDR1): Encodes P-glycoprotein, a transporter that facilitates drug efflux through the gastrointestinal tract and blood-brain barrier.(36)

Drug Targets and Pharmacodynamics:

Genetic variations in drug targets, such as receptors, enzymes, and ion channels, can affect drug sensitivity and treatment results in addition to metabolism and transport. Examples consist of:

VKORC1: By changing the target enzyme of vitamin K antagonism, variants impact warfarin sensitivity.(26,36)

- HER2, EGFR, KRAS, and BRAF: Targeted medicines in oncology are guided by somatic mutations in these genes in cancer cells.
- HLA alleles: Variants like HLA-B57:01 and HLA-B15:02 are linked to severe hypersensitivity reactions to carbamazepine and abacavir, respectively8. This is sometimes described as risk categories for drug toxicity or as a "metabolizer status" (e.g., poor vs. ultra-rapid metabolizer.(36)

Principal Advantages of Big Data & Pharmacogenomics in Oncology:-

Personalized Cancer Treatment: Instead of using "one-size-fits-all" chemotherapy, PGx enables medical professionals to customize cancer treatments depending on a patient's genetic composition. (38) Decreased Toxicity and Better Results: Physicians can anticipate drug metabolism and lessen severe adverse drug reactions (ADRs) and treatment failures by discovering genetic markers such as CYP2D6 for tamoxifen. (57)

Enhanced Drug Efficacy (focused Therapy): By identifying actionable mutations (such as BCR-ABL for imatinib) through genomic testing, highly focused medicines can be used with greater efficacy.(56)

Cost-Effectiveness and Efficiency: Pharmacogenomics reduces hospitalizations for adverse events and trial-and-error prescriptions, which lowers healthcare costs. For example, identifying patients at risk of toxicity using DPYD variant testing can save therapy management expenses.(49)

Role of Big Data Integration:Big data mining supports the discovery of new drug-gene interactions and helps clinical decision-making by aggregating data from electronic health records.(55) Optimized Drug Development:Pharmacogenomic research, supported by big data, improves the safety and efficacy of new drug trials. (29)



Figure 2: Benefits of pharmacogenomics

Chemotherapy's function and drawbacks in the treatment of cancer:-

Chemotherapy involves the use of cytotoxic or cytostatic medications that are either cell cycle-specific or do not target a specific stage of the mitotic cycle. This feature is crucial for combination treatments where it is anticipated that chemotherapy may enhance the effects of radiation, most frequently through cellular sensitization.(11,28)The pharmacology, clearance, adverse effects, molecular mode of action, and biochemical structure of drugs vary. These qualities make them suitable for aspecific histology or anatomical location. Different medication classes have distinct cytotoxic processes, and it is anticipated that their combination with radiation may increase radiotherapy's anti-tumor efficacy. (6) Although there have been significant advancements in chemotherapeutic agents over the past few decades, there are still a number of issues that limit their effectiveness in solid tumors: optimal dosage, drug resistance and cross-resistance to multiple agents, side effects (some of which are irreversible), optimal timing between chemotherapy and other treatments (such as surgery, radiotherapy,

immunotherapy, etc.), repopulation between cycles of chemotherapy, and incomplete knowledge of the pharmacokinetics and pharmacodynamics of a particular agent (Figure 2). Among the aforementioned difficulties, normal tissue toxicity and resistance to chemotherapeutic drugs are arguably the most frequent barriers to attaining the best outcomes.(2)Chemotherapeutic agents from various pharmacological classes (see Table 1) are frequently combined in so-called cocktails to prevent poor tumor response to a particular agent caused by drug resistance. Increased normal tissue toxicity is a drawback of multi-agent chemotherapy, and when paired with radiation-induced toxicity, it frequently results in serious side effects. varied drug classes typically have varied adverse effects, but they all have an impact on quickly reproducing cells regardless of whether they are malignant or healthy. (2) Furthermore, it has been demonstrated that alkylating agents raise the risk of leukemia five to ten years after treatment, anthracyclines can result in permanent cardiac lesions when taken in high doses, topoisomerase inhibitors raise the risk of second cancers,and taxases are associated with an increased risk of nerve damage.



Figure 2:- managing side effects of chemotherapy

Which have improved sparing of nearby vital organs and increased dosage conformality, but this is not the case with chemotherapy, where drug-related side effects continue to be a dose-limiting factor. (31)Furthermore, the use of chemotherapy in conjunction with radiation therapy frequently results in extra side effects due to drug-radiation interaction, a problem with a number of gaps that need to be filled. Preclinical evidence is either insufficient or nonexistent, or preclinical results are not adequately translated into clinical settings, which leads to suboptimal outcomes from trials using specific drug–radiation combos.(27)Chemotherapy is thought to have reached a plateau based on the state of systemic drug therapy and will not advance further unless research directions are shifted to individualized and biomarker-guided therapeutic techniques.(29).The results of clinical trials have demonstrated that, despite the stringent eligibility requirements used by the trial, there is typically a subgroup of patients that responds to therapy optimally with minimal toxicity, while another category of patients exhibits crippling side effects and/or poor tumor control. (6,28) An important question about patient classification and treatment personalization is raised by the fact that cancer patients with the same histological and immuno histochemical markers have varying treatment outcomes. In order to advance the field of individualized therapy, it is essential to identify all clinical and patient-related factors that affect how well a patient responds to treatment (like chemotherapy) and to compile the data into databases that are accessible to all interested researchers for additional processing and interpretation.(27,31)

Difficulties and restrictions:-

Widespread adoption of pharmacogenomics confronts many obstacles, despite mounting evidence of its therapeutic value and revolutionary possibilities in personalized medicine. These restrictions apply to the fields of science, medicine, economics, ethics, and infrastructure. For pharmacogenomics to be successfully incorporated into standard treatment, these obstacles must be recognized and addressed. (51)

1. Limited Clinical Implementation:-

Despite the availability and validation of a number of pharmacogenomic assays, many healthcare systems have been sluggish to incorporate them into standard practice. (27,51) Among the reasons are:

• Lack of clinician education and awareness: Many doctors and pharmacists are either untrained in genetics or lack confidence when interpreting the results of genetic tests.

• Uncertain clinical guidelines: Standardized guidelines are either nonexistent or neglected, and data for many gene-drug pairings is still developing.(32)

• Problems with workflow integration: Without specialized infrastructure, integrating genetic testing into hectic clinical environments can be difficult and time-consuming.

2. Cost and Reimbursement Issues:

Pharmacogenomic testing is still very expensive, especially in environments with limited resources. Many tests are not covered by insurance, particularly when the clinical benefit is still being studied.

3. Ethical, Legal, and Social Implications (ELSI):

Using genetic data presents difficult ethical and legal issues, especially in relation to permission, privacy, and possible discrimination.

• Genetic data privacy: Patients may be worried about how their genetic data is shared or preserved, as well as who can access it. (34)

• Informed consent: It's still difficult to make sure people are completely aware of the consequences of genetic testing.

• Discrimination risks: Fear of discrimination by employers or insurers endures despite legal protections in many nations (such as the Genetic Information Non-discrimination Act in the United States).

4. Population Diversity and Generalizability:

Studies largely targeting people of European ancestry have produced a large portion of the pharmacogenomic data used to inform treatment decisions. As a result, there is a significant application gap for populations with different ethnic backgrounds.(32)

•Variability in Allele Frequencies: The incidence of significant pharmacogenetic variations varies among populations, and some may be completely population-specific.

6. Regulatory and Policy Barriers:

Various regional regulatory frameworks impede the development of pharmacogenomic tests and their incorporation into healthcare.

• Lack of international standardization: Different regulatory agencies' (such as the FDA, EMA, and PMDA) guidelines may cause misunderstandings or implementation delays.

• Approval procedure: Companion diagnostics must be connected to particular medication labels and may necessitate intricate, drawn-out approval procedures. (31)

7. Infrastructure and Data Management:

A strong infrastructure is needed to implement pharmacogenomics at scale, including:

• Integration of electronic health records (EHRs): The majority of healthcare systems are currently unable to instantly integrate genetic data into patient records.

• Clinical decision support systems (CDSS): In order to evaluate genetic results and make well-informed treatment decisions, doctors require these tools.

8. Gaps in Training and Education: Education at all levels—medical students, practicing physicians, pharmacists, and patients—is crucial to bridging the gap between genetic science and clinical practice.

• Limited inclusion in medical curricula: Pharmacogenomics is not taught to many medical professionals during their training.

• Continuing education needs: Ongoing professional development opportunities are necessary to keep pace with rapidly evolving knowledge(34)

The secret to customized chemotherapy is pharmacogenomics: -

Pharmacogenomics may be crucial in managing cancer by tailoring chemotherapy to a patient's genetic composition and addressing the variety of acute and long-term adverse effects that arise from both anticipated and unexpected reactions to chemotherapeutic drugs. Furthermore, a wide variety of healthy tissues are impacted by the cocktail-style administration of cancer medications for improved tumor response, making side effect management more challenging.(14) As previously indicated, identifying patient-specific characteristics that contribute to inter-patient heterogeneity in treatment response is crucial to research advancements in tailored chemotherapy. NCI-MATCH (National Cancer Institute – Molecular Analysis for Therapy Choice) and NCI-ComboMATCH, two sizable precision medicine clinical studies that seek to match the therapeutic medication with the individual's genetic characteristics, should be mentioned in this context. As a result, patients enrolled in these trials are assigned a treatment according to the genetic alterations found in their cancer cells using genomic sequencing, with the main purpose being to ascertain the objective response rate and progression-free survival/side effects as secondary goals.(48,60) The two trials look at targeted medications instead of traditional medications.Overcoming drug resistance to single-agent treatment through genomic-specific targeting with combination medicines is a major objective of this latter trial. Numerous medications and malignancies have already had results from NCI-MATCH trial arms published; the most recent studies, which are compiled in Table 2, show mixed results, some of which call for additional research. It is anticipated that developments in DNA technology, such as next-generation sequencing (also known as massively parallel sequencing, a high-throughput DNA sequencing that allows the evaluation of a patient's entire genomic sequence through parallel processing), will transform cancer genomics and enable a better understanding of carcinogenesis through the identification of new driver genes and mutagenetic patterns.(27,51) Conventional chemotherapy is also the subject of genetic study, which focuses on two key features of chemotherapy effects: drug resistance and normal tissue damage. Numerous genetic changes and pathways unique to cancer have been linked to drug resistance, but the function of other genetic mechanisms in drug resistance still needs to be clarified.(60) Similarly, the genes responsible for severe toxicity of a number of chemotherapeutic drugs have been identified, and efforts are being made to update treatment protocols with genotype testing criteria for treatment advice and adaptation.

Table: 2 Summary of drug-cancer matching studies for personalized therapy based on the NCI-MATCH trial.

Drug/reference	Cancer type/characteristics	Trial results/observations
Erdafitinib28	Cancers with FGFR1–4 mutations or fusions	Primary endpoint (objective response rate) was met in patients with pretreated solid tumours; erdafitinib showed effectiveness in patients with FGFR-altered cancers outside of currently approved indications.
Trastuzumab/ Pertuzumab29	HER2-amplified cancers (non-breast/ gastroesophageal)	The combined drug was active without meeting the set efficacy goal. Further research into resistance pathways and HER2 targeting strategies is justified.
Osimertinib30	Cancers with EGFR mutations (T790M or rare activating)	Primary endpoint was not met for efficacy; responses were observed in neuroendocrine and epithelial carcinoma with rare EGFR mutations.
Palbociclib31	Cancers with CCND1, 2 or 3 amplification and expression of the retinoblastoma protein	Palbociclib was not effective at treating non-breast solid cancers with a CCND1, 2 or 3 amplification; further research is not warranted with palbociclib as single agent.
Trametinib32	Cancers with NF1 or GNA11/Q-mutations	Primary endpoint was not met for efficacy; yet, significant responses and prolonged stable disease in some disease subtypes warrant further investigation.

Medical oncology using big data since the late 1990s:-

A collection of data that is "too large for traditional tools and approaches" has been referred to as "big data." The aforementioned description is purposefully ambiguous because the boundaries of what is deemed "too large" are continually shifting due to ongoing technological advancements. Big Data, in its broadest sense, includes not only the data itself but also the techniques employed for data analysis and information extraction. Although Big Data sets are collections of structured, semi-structured, and unstructured data, it is simple to conceive of Big Data as an expanded ordinary database. in medical oncology studies.(23) A Big Data set's volume of information is its primary feature. It's interesting to remember that while information has always existed historically, data has not because the information was not being recorded. Fitness equipment and personal monitoring are only two of the many new facets of healthcare that have been captured and stored in the digital era. The amount of data being gathered is growing quickly, not just due to theincorporation of these new sources as well as the increasingly thorough information gathering from conventional sources, resulting in a data pool that is both larger and more finely defined in its representation of the information. A Big Data set's diversity in kind and nature is another feature.(12) Like semi-structured data (such as medical photographs kept in a structured database but representing an unstructured source of information), structured data, such as test findings, is a part of a data set. The electronic health records (EHRs), which store text-based data entered by numerous medical experts over an extended period of time for each patient, are a vital and rich source of information that is completely unstructured. Studies conducted on datasets often use a snapshot of the data, treating it as a static collection of information. However, in reality, new data is constantly being added, therefore the storage infrastructure must be able to handle this. Doug Laney44 first proposed the three V-s of big

data—volume, variety, and velocity—in a 2001 Meta Group research publication (Figure 3). (50)Since then, additional attributes have been added to more fully characterize a Big Data set, such as value (the importance of the stored information in relation to the dataset goals), veracity (the accuracy and dependability of the information), and variability (the irregularity of the information structure) It is clear from the features of a Big Data collection that the storage infrastructure is one of the key components of a Big Data project. The relational architecture of a database has historically been used for information storage, offering a somewhat simple notion and a clear method of interaction through the Structured Query Language (SQL) language. The constraints of relational databases that strictly follow the ACID transactions principle have come to light with the emergence of Big Data sets.(7,25). This schema-oriented paradigm expects data to be organized in accordance with the specified schema, which is not necessarily the case in a Big Data collection with several information sources. The three V-s, which indicate that a parallel infrastructure that can scale horizontally on numerous devices or the cloud is more suitable for the task, are completed by the velocity of the incoming data for a Big Data collection.(50) These restrictions can be circumvented using a novel database paradigm known as NoSQL. This architecture can grow over massive computing infrastructures and lacks a predetermined schema. For instance, the NoSQL key-value store approach is similar to a dictionary in which a value is linked to a unique key. Parallel operations spread across massive infrastructures are a good fit for this architecture.(12)



Figure 3:- Big data in oncology flow.

New technologies and future paths:

Pharmacogenomics is moving from research settings into standard clinical practice as our knowledge of gene-drug interactions expands and the cost of genetic analysis keeps falling. This section examines new technologies that are expanding pharmacogenomics' capabilities and highlights major developments that will probably influence its future.(33)

- Both known and unknown pharmacogenomic variations can be found using whole genome sequencing (WGS) and whole exome sequencing (WES).
- NGS platforms are able to examine several pharmacogenes at once, unlike single-gene assays.(4)

1. Artificial Intelligence and Machine Learning:

The interpretation of complicated genomic data and the prediction of medication responses are becoming more and more dependent on artificial intelligence (AI) and machine learning (ML).

• To customize treatment regimens, predictive modeling can incorporate environmental, clinical, and genomic data. (52)

• Clinical decision support systems (CDSS) powered by AI are being developed to offer evidence-based, real-time suggestions at the point of care.

• By examining big datasets from biobanks and clinical trials, machine learning algorithms are also helping to find new pharmacogenomic biomarkers.(29)

2. Electronic Health Records (EHR) Integration:

To convert genomic insights into therapeutic action, pharmacogenomic data must be integrated into electronic health records.

• To store, update, and flag pertinent genetic data, EHR systems are being improved.

• These methods have been pioneered by organizations including St. Jude Children's Research Hospital and Vanderbilt University Medical Center, which have shown increased prescribing efficiency and safety.(61)

3. Multi-omics and Pharmacoepigenomics: Methods:Beyond genetics, further understanding of interindividual variation in medication response is provided by transcriptomics, proteomics, metabolomics, and epigenetic changes.
• Pharmacoepigenomics examines how gene expression linked to medication metabolism and efficacy is impacted by DNA methylation, histone modification, and non-coding RNAs.

• By improving current pharmacogenomic models and finding new predictive biomarkers, multi-omics integration may result in more precise, individualized treatments.(33)

4. DTC, or direct-to-consumer Genetic Testing:

As DTC genetic tests become more widely available, pharmacogenomics is becoming more widely known, and people are becoming empowered to make their own health decisions.

• Although their clinical value may vary, companies like 23andMe provide customers with limited pharmacogenomic data directly.

• Although DTC testing makes genomic data more accessible to the general public, it also raises questions about regulatory supervision, accurate interpretation, and making educated decisions without medical advice.(4)

5. Pharmacogenomics in Global Health:

Attempts are being made to extend the advantages of pharmacogenomics outside of wealthy nations.

• Recognizing that genetic variation varies greatly among ethnic groups, global pharmacogenomics programs seek to create population-specific databases.

• Collaborations between governments, academic institutions, and international organizations are assisting in the development of capacity in low- and middle-income nations.(66,39)

Pharmacogenomics application in clinical settings Present situation:-

The application of pharmacogenomics in clinical settings is the goal of contemporary pharmacological research. Numerous organizations in the US, Europe, and Asia have

started initiatives in this area.(65,66)The University of Colorado undertook research to enable a preemptive return of clinical pharmacogenomic data utilizing a research biobank. This study is among the most recent single-institution publications on the clinical implementation of pharmacogenomics.. There are also large-scale initiatives to encourage implementation of pharmacogenomics research results in clinical practice. The CPIC in the United States(52,53) and the Ubiquitous Pharmacogenomics programme in Europe are two extensive pro-jects that aim to establish a healthcare system that will allow effective treatment optimization based on pharmacogenomics results. The CPIC was established in 2009 as a shared project between PharmGKB and the National Institute of Health (NIH) to overcome one of the greatest obstacles in clinica pharmacogenomics: the translation of genetic testing results into actionable prescribing decisions for a specific drug. Their key aim was to create, curate and dis-tribute freely available, evidence-based and peer-reviewed clinical practice guidelines regarding drug–gene interaction to facilitate bench-to-bed-side translation of knowledge.78 Until 2020, CPIC has published 23 guidelines encompassing data on 19 genes and 46 drugs, covering various therapeu-tic areas.(42) The Consortium is now known as the gold standard source for clinical pharmacogenetics implementation due to the extensive usage of their resources and the international application of their guidelines, which have resulted from the exposure and recognition of their scientific achievement over the previous decade.(66) The creation of prioritization recommendations, which determine which pharmacogenetic tests and medications should be put into clinical use based on the degrees of actionability attributed to drug-gene pairings, is a significant factor taken into account by the Consortium. Additionally, CPIC offers the most recent data on drug-gene.(62)

CONCLUSION: -

Pharmacogenomics has the potential to revolutionize contemporary medicine by improving the safety, efficacy, and personalization of medication therapy. Even if there are still obstacles to overcome, systemic healthcare changes, ongoing research, and technological advancements will hasten its acceptance. Personalized medicine is a developing reality that is changing the therapeutic landscape, not some far-off future. Pharmacogenomics holds tremendous promise for revolutionizing personalized medicine by tailoring drug therapy toindividual patients based on their genetic makeup. Despite challenges in implementation and ethical considerations, ongoing research and innovation in pharmacogenomics can improve treatment outcomes, enhance patient safety, and transform healthcare delivery. By addressing these challenges and advancing our understanding of the genetic basis of drug response, pharmacogenomics has the power to usher in a new era of precision medicine. Pharmacogenomics is a cornerstone of modern precision oncology, with the potential to transform cancer treatment by personalizing therapy based on genetic profiles. The critical roles that genetic markers including CYP2D6, DPYD, and UGT1A1 play in affecting drug metabolism, effectiveness, and toxicity have been emphasized in the review. In the treatment of lung, gastrointestinal, and breast cancers, among other conditions, pharmacogenomic testing can direct treatment and reduce the possibility of serious side effects, demonstrating the therapeutic significance of these biomarkers. The increasing significance of DPYD and UGT1A1 testing to enhance medication safety, especially in patients on regimens based on irinotecan and

fluoropyrimidines, is one of the main conclusions. A more thorough assessment of drug response and toxicity risks is provided by novel multi-gene techniques that combine indicators like TYMS and MTHFR with DPYD testing. Furthermore, the advancement of sophisticated computational models and liquid biopsies shows potential for non-invasive pharmacogenomic testing.

REFERENCES

1. ACS Journals: Modern developments in germline pharmacogenomics for oncology.
2. Ang KK, Zhang Q, Rosenthal DI, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 2014; 32: 2940–2950.
3. Ang HX, Chan SL, Sani LL, et al. Pharmacogenomics in Asia: a systematic review on current trends and novel discoveries. Pharmacogenomics 2017; 18(9): 891–910.
4. Amir-Aslani A, Mangematin V. The future of drug discovery and development: shifting emphasis towards personalized medicine. Technological Forecasting and Social Change. 2010 Feb 1; 77(2):203-17.
5. Aquilante CL, Kao DP, Trinkley KE, et al. Clinical implementation of pharmacogenomics via a health system-wide research Biobank: the University of Colorado experience. Pharmacogenomics 2020; 21(6): 375–386.
6. Azarova AM, Lyu YL, Lin CP, et al. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc Natl Acad Sci U S A 2007; 104(26): 11014–11019.
7. Carrera-Pacheco SE, Mueller A, Puente-Pineda JA, et al. Designing cytochrome P450 enzymes for use in cancer gene therapy. Front Bioeng Biotechnol 2024; 12: 1405466.
8. Caudle, K. E., Dunnenberger, H. M., Freimuth,R. R., Peterson, J. F., Burlison, J. D., Whirl-Carrillo, M., ... & Hoffman, J. M. (2020). Standardizing terms for clinicalpharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genetics in Medicine, 22(3), 503-505.
9. Crews, K. R., Gaedigk, A., Dunnenberger, H.M., Leeder, J. S., Klein, T. E., Caudle, K.E., & Haidar, C. E. (2014). Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clinical Pharmacologyand Therapeutics, 95(4), 376-382.
10. Dahary D, Golan Y, Mazor Y, et al. Genome analysis and knowledge-driven variant interpretation with TGex. BMC Med Genomics 2019; 12(1): 200.
11. Davies SM. Therapy-related leukemia associated with alkylating agents. Med Pediatr Oncol 2001; 36(5): 536–540.
12. Dunnenberger HM, Crews KR, Hoffman JM, et al. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu Rev Pharmacol Toxicol2015; 55: 89–106.
13. Evans, W. E., & Relling, M. V. (1999).Pharmacogenomics: translating functional genomics into rational therapeutics. Science,286(5439), 487-491.
14. Fleming N. How artificial intelligence is changing drug discovery. Nature 2018; 557: S55–S57
15. Gong J, Mita AC, Wei Z, et al. Phase II study of erdafitinib in patients with tumors with FGFR amplifications: results from the NCI-MATCH ECOG-ACRIN trial (EAY131)

subprotocol K1. JCO Precis Oncol 2024; 8: e2300406.
16. Gottesman O, Scott SA, Ellis SB, et al. The CLIPMERGE PGx program: clinicalimplementation of personalized medicine through electronic health records and genomics-pharmacogenomics. Clin Pharmacol Ther 2013; 94(2): 214–217.
17. Haerder T and Reuter A. Principles of transaction-oriented database recovery. ACM Comput Surv 1983; 15(4): 287–317.
18. Hasanzad M, Sarhangi N, Hashemian L, Sarrami B. Principles of pharmacogenomics and pharmacogenetics. In Precision Medicine in Clinical Practice 2022 Oct 1 (pp. 13-32). Singapore: Springer Nature Singapore.
19. Hoffman JM, Haidar CE, Wilkinson MR, et al. PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. Am J Med Genet C Semin Med Genet 2014; 166C(1): 45–55.
20. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature. 2001;409(6822):860-921.
21. Innocent F, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004;22(8):1382-8.
22. Johnson JA, Burkley BM, Langaee TY, et al. Implementing personalized medicine: development of a cost-effective customized pharmacogenetics genotyping array. Clin Pharmacol Ther 2012; 92(4): 437–439.
23. Just KS, Steffens M, Swen JJ, et al. Medical education in pharmacogenomics – results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx). Eur J Clin Pharmacol 2017; 73(10): 1247–1252
24. Kalinin AA, Higgins GA, Reamaroon N, et al. Deep learning in pharmacogenomics: from gene regulation to patient stratification. Pharmacogenomics 2018; 19(7): 629–650.
25. Krebs K and Milani L. Translating pharmacogenomics into clinical decisions: do not let the perfect be the enemy of the good. Hum Genomics 2019; 13(1): 39.
26. Kelton T. Pharmacogenomics: The rediscovery of the concept of tailored drug therapy and personalized medicine. Health Law.2006; 19:1.
27. Laney D. 3D data management: controlling data volume, velocity and variety. META Group Research Note, 6, 2001.
28. Lam YF. Principles of pharmacogenomics: pharmacokinetic, pharmacodynamic, and clinical implications. InPharmacogenomics 2019 Jan 1 (pp. 1-53). Academic Press.
29. Lin SH, Willers H, Krishnan S, et al. Moving beyond the standard of care: accelerate testing of radiation–drug combinations. Int J Radiat Oncol Biol Phys 2021; 111(5): 1131–1139.
30. Lotrionte M, Biondi-Zoccai G, Abbate A, et al. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol 2013; 112(12): 1980–1984.
31. LWW: Transforming medicine through pharmacogenomics
32. Lynch TJ, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung c
33. Maddalo M, Borghetti P, Tomasini D, et al. Cetuximab and radiation therapy versus cisplatin and radiation therapy for locally advanced head and neck cancer: long-term survival and toxicity outcomes of a randomized phase 2 trial. Int J Radiat Oncol Biol Phys 2020; 107: 469–477.
34. Morganti S, Tarantino P, Ferraro E, D'Amico P, Duso BA, Curigliano G. Next generation

sequencing (NGS): a revolutionary technology in pharmacogenomics and personalized medicine in cancer. Translational Research and Onco-omics Applications in the Era of Cancer Personal Genomics. 2019: 9-30.
35. Morganti S, Tarantino P, Ferraro E, D'Amico P, Duso BA, Curigliano G. Next generation sequencing (NGS): a revolutionary technology in pharmacogenomics and personalized medicine in cancer. Translational Research and Onco-omics Applications in the Era of Cancer Personal Genomics. 2019: 9-30.
36. NCI-ComboMATCH, https://ecog-acrin.org/nci-combomatch (accessed April 2024).
37. Ncoda.org: Measuring the Economic Value of Pharmacogenomics in Oncology
38. O'Donnell PH, Danahey K, Jacobs M, et al. Adoption of a clinical pharmacogenomics implementation program during outpatient care – initial results of the University of Chicago '1,200 Patients Project'. Am J Med Genet C Semin Med Genet 2014; 166C(1): 68–75.
39. Palumbo S, Mariotti V, Pellegrini S. A narrative review on pharmacogenomics in psychiatry: scientific definitions, principles, and practical resources. Journal of Clinical Psychopharmacology.
40. Phillips, K. A., Veenstra, D. L., Oren, E., Lee, J.K., Sadee, W., & Haddow, J. E. (2014). Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA,281(10), 927-934.
41. PMC - NIH: Pharmacogenomics and Big Data in medical oncology
42. Relling MV and Klein TE. CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther 2011; 89(3): 464–467.
43. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium. Clin Pharmacol Ther. 2011;89(3):464-7.
44. Relling MV, Klein TE, Gammal RS, et al. The clinical pharmacogenetics implementation consortium: 10 years later. Clin Pharmacol Ther 2020; 107(1): 171–175.
45. Rivera E and Cianfrocca M. Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol 2015; 75(4): 659–670.
46. Shuldiner AR, Palmer K, Pakyz RE, et al. Implementation of pharmacogenetics: the University of Maryland personalized anti-platelet pharmacogenetics program. Am J Med Genet C Semin Med Genet 2014; 166C(1): 76–84.
47. Sage Journals: Pharmacogenomics and Big Data in medical oncology
48. Slamon DJ, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-92.
49. Springer Link: Pharmacogenomics and Cancer Treatment.Historical Milestones of Pharmacogenomics in Medical Oncology_With references – for your review article Section 2.1_
50. Springer Nature Link: Pharmacogenomics and Cancer Treatment
51. Strohbach M, Daubert J, Ravkin H, et al. Big data storage. In: Cavanillas J, Curry E and Wahlster W (eds) New horizons for a data-driven economy, pp.1–324. Berlin: Springer, 2016.
52. Tandfonline 000112043: Pharmacogenetics and Pharmacogenomics in Oncology.
53. Teer JK. An improved understanding of cancer genomics through massively parallel

sequencing. Transl Cancer Res 2014; 3(3): 243–259.
54. Thermofisher: Integrating pharmacogenomics into the standard of care
55. van Schaik RH. CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Updat2008; 11(3): 77–98.
56. Vizirianakis IS. Challenges in current drug delivery from the potential application of pharmacogenomics and personalized medicine in clinical practice. Current Drug Delivery. 2004 Jan 1;1(1): 73-80.
57. Volpi S, Bult CJ, Chisholm RL, et al. Research directions in the clinical implementation of pharmacogenomics: an overview of US programs and projects. Clin Pharmacol Ther 2018; 103(5): 778–786.
58. van der Wouden CH, Cambon-Thomsen A, Cecchin E, et al. Implementing pharmacogenomics in Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium. Clin Pharmacol Ther 2017; 101(3): 341–358.
59. Wang Y, Zhang S, Li F, et al. Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics. Nucleic Acids Res 2020; 48(D1): D1031–D1041.
60. Whirl-Carrillo M, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92(4):414-7.15. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium. Clin Pharmacol Ther. 2011;89(3):464-7.
61. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980;32(5):651-62.
62. Williams MS. Early lessons from the implementation of genomic medicine programs. Annu Rev Genomics Hum Genet 2019; 20: 389–411
63. Zubiaur P, Mejía-Abril G, Navares-Gómez M, et al. PriME-PGx: La Princesa University Hospital multidisciplinary initiative for the implementation of pharmacogenetics. J Clin Med2021; 10(17): 3772.

HOW TO CITE: Dhanashree Somawanshi*, Dhanashri Gosavi, Devesh Bhavsar, Pharmacogenomics and Big Data in Medical Oncology: - Development, Integration Challenges and Future Perspectives., Int. J. of Pharm. Sci., 2026, Vol 4, Issue 5, 7033-7049. https://doi.org/10.5281/zenodo.20403803